Relating to the Prescription Drug Affordability Board; prescribing an effective date.
Summary
House Bill 2599 directs the Oregon Prescription Drug Affordability Board to develop a plan that better aligns its work with the state’s Prescription Drug Price Transparency Act. The board must submit a report to legislative health committees by December 15, 2026, with recommendations for legislation that would focus the board’s efforts on prescription drugs showing the largest price increases or the greatest impact on health plan and overall health care spending.
The bill also asks for recommendations to align reporting requirements across the prescription drug supply chain, identify which entities should be covered by transparency reporting, and ensure reporting rules are consistent from one part of the supply chain to another. It specifically calls for protections for trade secrets and confidential information, including the use of aggregated data where appropriate. The measure is temporary, repealing its reporting directive on January 2, 2027, and it takes effect 91 days after adjournment of the 2025 legislative session.
Impact
HB2599 does not immediately change substantive drug pricing law, but it requires the Prescription Drug Affordability Board to produce recommendations that could lead to future amendments to ORS 646A.693 and the Prescription Drug Price Transparency Act. If acted on later by the Legislature, those recommendations could expand or refine transparency obligations, alter the board’s membership, and standardize reporting across the prescription drug supply chain. The bill affects the PDAB, health-related interim committees, and entities in the drug supply chain that may become subject to reporting requirements.
Sentiment
Based on the bill text alone and the absence of recorded committee testimony or votes, the measure appears to be a policy-development bill rather than a controversial enforcement change. Its focus on affordability, transparency, and legislative recommendations suggests a generally constructive or exploratory posture. No recorded votes or hearing comments are available in the provided materials to indicate support or opposition.
Contention
The main potential points of contention are likely to be the scope of prescription drug transparency reporting, which supply-chain entities should be included, and how to protect trade secrets and confidential business information while still requiring meaningful disclosure. Another possible issue is the proposed emphasis on certain high-cost or rapidly increasing drugs, which could be seen as either a targeted and efficient approach or as too narrow depending on stakeholder perspective. The bill also contemplates changes to board membership to include stakeholders subject to reporting, which may raise questions about representation, independence, and industry influence.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.